Atossa Therapeutics' (ATOS) "Buy" Rating Reaffirmed at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright's target price points to a potential upside of 334.78% from the company's previous close.

Other equities analysts also recently issued research reports about the company. StockNews.com raised Atossa Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, October 25th. Ascendiant Capital Markets boosted their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a "buy" rating in a report on Wednesday, September 11th.

Atossa Therapeutics Trading Down 2.1 %

Shares of Atossa Therapeutics stock traded down $0.03 on Thursday, reaching $1.38. 636,122 shares of the company were exchanged, compared to its average volume of 1,088,761. The company has a market capitalization of $173.54 million, a price-to-earnings ratio of -5.77 and a beta of 1.20. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31. The company has a 50-day moving average of $1.43 and a 200 day moving average of $1.38.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Analysts predict that Atossa Therapeutics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Atossa Therapeutics in the 2nd quarter valued at about $29,000. Cetera Advisors LLC bought a new stake in shares of Atossa Therapeutics in the first quarter valued at approximately $72,000. SG Americas Securities LLC grew its position in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares in the last quarter. Virtu Financial LLC bought a new position in Atossa Therapeutics during the 1st quarter worth $151,000. Finally, Rhumbline Advisers acquired a new position in Atossa Therapeutics in the 2nd quarter valued at $161,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.